You searched for "Stone"

1249 results found

The BSoT buddy scheme at BAUS 2023: a new initiative for fostering international relationships

The BSoT committee at BAUS, many of whom where involved with the inaugural buddy scheme. The buddy background By Nicholas Boxall, Specialty Registrar, Cambridge University Hospitals NHS Foundation Trust; Immediate Past Chair of BSoT. The BAUS Section of Trainees (BSoT)...

Multiparametric MRI with targeted-only biopsy – a new standard?

In this issue of European Urology, Kasivisvanathan et al. present a meta-analysis of two randomised trials comparing prebiopsy MRI with targeted biopsy (TBx) alone versus standard transrectal ultrasound-guided biopsy (TRUS-Bx) in biopsy-naïve men at risk of prostate cancer. Their findings...

The case against omitting systematic biopsy in younger men

In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...

iMEDicare's fundraiser for Disabled Living/Bladder and Bowel UK

Team iMEDicare Execs will climb the tallest mountain in Poland (Mount Rysy in the Tatra Mountains – 8,199 feet/2,499 metres), on the 27th of August 2023.

Synthetic mid-urethral slings for stress incontinence in neurogenic LUTD

Neurogenic lower urinary tract dysfunction (NLUTD) is heterogeneous because of the multiplicity of underlying causes and mechanisms. In women with NLUTD, stress urinary incontinence may be due to intrinsic sphincter deficiency caused by the neurological disease itself or from sphincter...

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy

There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...

Hail the Portfolio Pathway!

In the United Kingdom, the pursuit of a surgical career traditionally follows a conventional pathway, primarily through the completion of specialty programmes accredited by the Royal College of Surgeons or the Intercollegiate Surgical Curriculum Programme (ISCP). However, for doctors with...

Frailty in urology – part 2

The first article in this series defined frailty and introduced the concept and importance of identifying patients living with frailty who undergo surgery, including those undergoing urological procedures. In the second part of this series we outline how to identify...

Femeda Ltd Wins Prestigious Medilink Partnership with Academia Award

Femeda has committed to the first real world clinical trial for a consumer medical device globally to be run in Manchester. Femeda is extending the partnership with engagement of Phd students from...

Prolapse surgery with mesh: where do we stand in 2017? An ICS update

Background Surgery for pelvic organ prolapse (POP) is common among women. The lifetime risk of undergoing at least one surgical procedure for POP is up to 20% [1]. This kind of surgery will be increasingly important due to an ageing...

Urological Men’s Health – A guide for Urologists and Primary Care Physicians

Urologists, perhaps more than any other group of clinicians, can quite reasonably lay claim to be the champions for men’s health. But are we particularly well placed to deliver? This text is aimed at primary care physicians and those urologists...

Junior doctors’ strike: is there light at the end of the tunnel?

Most urology departments will be affected one way or another by the ongoing industrial action by our junior colleagues. This article gives an interview between the BMJ team and Jeremy Hunt, UK Secretary of State for Health. We may or...